阅读说明：本技术 氨基氧乙酸在制备预防或治疗心梗的药物中的应用 (Application of aminooxyacetic acid in preparing medicine for preventing or treating myocardial infarction ) 是由 陈维倩 周文静 赵培 沈振亚 惠杰 于 2019-10-18 设计创作，主要内容包括：本发明公开了氨基氧乙酸在制备预防或治疗心梗的药物或保健品中的应用；氨基氧乙酸改善心梗后心功能,减小心梗面积,从而可以预防或者治疗心梗。(The invention discloses an application of aminooxyacetic acid in preparing a medicament or a health-care product for preventing or treating myocardial infarction; the aminooxyacetic acid improves the cardiac function after myocardial infarction and reduces the myocardial infarction area, thereby preventing or treating myocardial infarction.)

1. Application of aminooxyacetic acid in preparing medicine for preventing or treating myocardial infarction is disclosed.

2. The use according to claim 1, wherein the medicament is an injectable formulation.

3. The use according to claim 1, wherein the aminooxyacetic acid improves post-myocardial function.

4. The use according to claim 1, wherein the aminooxyacetic acid reduces myocardial infarct size.

5. Application of aminooxyacetic acid in preparing medicine for improving myocardial function after myocardial infarction is disclosed.

6. The use according to claim 5, wherein the medicament is an injectable formulation.

7. Application of aminooxyacetic acid in preparing medicine for reducing myocardial infarction area is disclosed.

8. The use according to claim 7, wherein the medicament is an injectable formulation.

9. Application of aminooxyacetic acid in preparing health products for preventing myocardial infarction is provided.

10. The use according to claim 9, wherein the health product is an injectable product.

Technical Field

The invention belongs to the medicine technology, and particularly relates to an application of aminooxyacetic acid in preparing a medicine for preventing or treating acute myocardial infarction.

Background

Myocardial infarction is a cardiovascular disease seriously harming human health, and the incidence of ischemic myocardial infarction is continuously increased along with the continuous improvement of living standard of Chinese people. Ischemic myocardial infarction can lead to scarring, which in turn affects cardiac function. Most of the current medicines or apparatus treatments can only relieve symptoms, but can not reverse the damage of heart tissues. Although heart transplantation can completely improve the heart condition, the heart transplantation is difficult to be widely applied clinically due to factors such as donor source scarcity, immunological rejection, expensive treatment cost and the like. At present, the application of aminoxyacetic acid (AOAA) in preparing a medicament for treating liver cancer of liver cells is reported, but no research report on the aspect of using aminoxyacetic acid for treating myocardial infarction is found so far.

Disclosure of Invention

In order to solve the problems in the prior art, the invention aims to provide a new application of AOAA in improving the cardiac function after myocardial infarction.

The invention discloses an application of aminooxyacetic acid in preparing a medicament or a health-care product for preventing or treating myocardial infarction.

In the invention, the medicine is an injection preparation.

The invention relates to an application of AOAA in preparing a medicine or a health-care product for preventing or treating myocardial infarction, in particular to an application of AOAA in preparing a medicine for protecting or treating myocardial infarction, and a specific administration mode can adopt intraperitoneal injection and the like.

The invention selects about 25g of C57BL/6J male mice as experimental objects, adopts a left coronary artery anterior descending ligation method to manufacture the myocardial infarction model, and the experiment meets the statistical requirements. After the abdominal cavity injection anesthesia, the patient is intubated through an oral trachea, and then connected with an air respirator, the breathing frequency is 110 times/min, the tidal volume is 3ml, and the respiratory suction ratio is 1: 1.3. In the right lateral position, the lateral skin of the left chest is incised through the left longitudinal incision, the pectoralis major is peeled off, the chest is opened through the third and fourth intercostal transverse incisions, the heart is exposed, and the pericardium is torn open through forceps. The left coronary artery was visualized by a surgical microscope. The anterior descending coronary artery (LAD) is ligated together with a small amount of myocardial tissue at about 1.5mm from the lower edge of the left atrial appendage, the depth of the needle insertion is about 1 mm, and the width is controlled within 3 mm. Closing the chest layer by layer. After ligation, the white part from the ligation part to the apex of the heart can be seen by naked eyes, and the successful establishment of the myocardial infarction model is proved. Mice in the experimental group were subjected to intraperitoneal injection of AOAA (10 mg/kg/day) for 3 consecutive days after myocardial infarction, and then were fed conventionally. Placing a probe of a cardiac ultrasonic diagnostic apparatus on the anterior wall of a heart, taking a left ventricular two-dimensional short axis view at the level of papillary muscles, simultaneously recording M-type scanning, continuously measuring a left ventricular Ejection Fraction (EF), a shortened Fraction (FS), a left ventricular diastolic end diameter (LVEDD) and a left ventricular systolic end diameter (LVESD) in 3 cardiac cycles, detecting the cardiac function 28 days after the myocardial infarction, and significantly improving the cardiac function, ejection fraction and short axis shortening rate after the myocardial infarction by AOAA; mice were sacrificed 28 days after surgery, left ventricular tissue was taken for cardiac tissue staining and the treatment effect was observed. The staining procedure was performed according to conventional Masson, and observed and photographed under a normal light microscope. Analyzing the area of each part by adopting Image analysis software Image J, and calculating the myocardial infarction area/heart area; the 28-day infarct size after each myocardial infarction was observed by Masson staining, and AOAA was found to effectively reduce the myocardial infarct size.

The invention discloses an amino oxyacetic acid for improving the cardiac function after myocardial infarction and reducing the myocardial infarction area, thereby preventing or treating myocardial infarction.

Drawings

FIG. 1 is a schematic diagram of M-mode ultrasound of each group of hearts before and after myocardial infarction modeling;

FIG. 2 is a graph showing the dynamic change of Ejection Fraction (EF) 28 days after myocardial infarction;

FIG. 3 is a short-axis shortening (FS) dynamic change curve 28 days after myocardial infarction;

FIG. 4 shows the myocardial infarction followed by 28 days of Masson staining for each myocardial infarction surface;

FIG. 5 is a statistical analysis of myocardial infarction area of each group 28 days after myocardial infarction.

Detailed Description

The main materials and sources used were as follows:

c57BL/6J mice (provided by the showa research center for new drugs, suzhou, this experiment was approved by the ethical committee of the university of suzhou); small animal ventilators (shanghai alcote biotechnology limited, shanghai); surgical instruments (sixty-six vision, suzhou); suture (Shanghai Pudong gold ring medical supplies, Inc., Shanghai); small animal ultrasound imaging system (Visual sonic vevo 2100); aminooxyacetic Acid (AOAA) was purchased from sigma.

Establishment of mouse myocardial infarction model

About 25g of C57BL/6J male mice are selected as experimental objects, a left coronary artery anterior descending ligation method is adopted to manufacture a myocardial infarction model, and the experiment meets the statistical requirements. After the abdominal cavity injection anesthesia, the patient is intubated through an oral trachea, and then connected with an air respirator, the breathing frequency is 110 times/min, the tidal volume is 3ml, and the respiratory suction ratio is 1: 1.3. In the right lateral position, the lateral skin of the left chest is incised through the left longitudinal incision, the pectoralis major is peeled off, the chest is opened through the third and fourth intercostal transverse incisions, the heart is exposed, and the pericardium is torn open through forceps. The left coronary artery was visualized by a surgical microscope. The anterior descending coronary artery (LAD) is ligated together with a small amount of myocardial tissue at about 1.5mm from the lower edge of the left atrial appendage, the depth of the needle insertion is about 1 mm, and the width is controlled within 3 mm. Closing the chest layer by layer. After ligation, the white part from the ligation part to the apex of the heart can be seen by naked eyes, and the successful establishment of the myocardial infarction model is proved. Mice in the experimental group were injected with AOAA (10 mg/kg/day) intraperitoneally for 3 consecutive days after myocardial infarction, and mice in the control group were injected with an equivalent amount of sterile physiological saline as a control. Feeding in the same manner, and detecting the cardiac function and cardiac peduncle area after the cardiac peduncle.